National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedNijhawan AE, Kitchell E, Etherton SS
Half of 30-day hospital readmissions among HIV-infected patients are potentially preventable.
The researchers assessed whether readmissions among HIV-infected patients were potentially preventable using both published criteria and detailed chart review, how readmissions might have been prevented, and the phase of care deemed suboptimal (inpatient care, discharge planning, post-discharge). They found that among 130 individuals experiencing 30-day readmissions, about half were determined to be potentially preventable using published criteria (53 percent) or implicit chart review (48 percent).
AHRQ-funded; HS022418.
Citation: Nijhawan AE, Kitchell E, Etherton SS .
Half of 30-day hospital readmissions among HIV-infected patients are potentially preventable.
AIDS Patient Care STDS 2015 Sep;29(9):465-73. doi: 10.1089/apc.2015.0096..
Keywords: Human Immunodeficiency Virus (HIV), Hospital Readmissions, Electronic Health Records (EHRs), Patient-Centered Outcomes Research, Prevention
Hellinger FJ
AHRQ Author: Hellinger FJ
Measuring the cost effectiveness of HIV prevention interventions in the US: pitfalls and problems.
The author comments on a review of cost-effectiveness studies of four types of HIV prevention interventions in the US. He agrees with the primary conclusion of the review that more cost-effectiveness research is needed to fill the knowledge gaps of interventions related to prevention for HIV-positives, condom distribution, and policy initiatives, in order to help guide the most efficient use of resources.
AHRQ-authored.
Citation: Hellinger FJ .
Measuring the cost effectiveness of HIV prevention interventions in the US: pitfalls and problems.
Appl Health Econ Health Policy 2015 Apr;13(2):129-33. doi: 10.1007/s40258-015-0158-5..
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Healthcare Costs
Schackman BR, Fleishman JA, Su AE
AHRQ Author: Fleishman JA
The lifetime medical cost savings from preventing HIV in the United States.
The researchers sought to estimate the medical cost saved by averting 1 HIV infection in the United States. They found that the estimated discounted lifetime cost for persons who become HIV infected at age 35 is $326,500 (60% for antiretroviral medications, 15% for other medications, 25% nondrug costs.
AHRQ-authored; AHRQ-funded; 290201100007C.
Citation: Schackman BR, Fleishman JA, Su AE .
The lifetime medical cost savings from preventing HIV in the United States.
Med Care 2015 Apr;53(4):293-301. doi: 10.1097/mlr.0000000000000308..
Keywords: Medical Expenditure Panel Survey (MEPS), Healthcare Costs, Human Immunodeficiency Virus (HIV), Prevention